Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,548.00-3.14%ETH$2,578.97-4.90%GOLD$4,148.70-0.92%OIL$89.85+0.46%
Smart Investors Daily
SID Premium
RA

NASDAQ · RADX

Radiopharm Theranostics Limited

Healthcare · Biotechnology

$1.18

Down-$0.08 (-6.35%)

Updated Oct 7, 2026, 12:20 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.24M
P/E ratio
0
Dividend yield
0.00%
52-week range
$1.00 – $16.25
Volume
77.79K
Avg. volume
26.17K

Price performance · RADX

RADX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RADX closed at $1.18 after 21 trading sessions, down 44.34% for the selected period.

Last close
$1.18
Period change
-44.34%
Period low
$1.18
Period high
$2.12
Daily close
View OHLC price history
RADX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.28$1.28$1.16$1.1877.79K
Oct 5, 2026$1.39$1.40$1.00$1.2782.4K
Oct 2, 2026$1.44$1.65$1.40$1.4262.32K
Oct 1, 2026$1.48$1.55$1.40$1.4848.04K
Sep 30, 2026$1.60$1.63$1.43$1.6263.41K
Sep 29, 2026$1.54$1.60$1.47$1.5243.39K
Sep 28, 2026$1.60$1.80$1.52$1.5243.97K
Sep 25, 2026$1.57$1.68$1.4407$1.6537.8K
Sep 24, 2026$1.61$1.68$1.485$1.571959.94K
Sep 23, 2026$1.65$1.6899$1.49$1.62535.68K
Sep 22, 2026$1.69$1.69$1.50$1.6533.43K
Sep 21, 2026$1.73$1.75$1.60$1.6135.97K
Sep 18, 2026$1.74$1.8415$1.65$1.6536.84K
Sep 17, 2026$1.70$1.91$1.70$1.7366.49K
Sep 16, 2026$1.56$1.80$1.55$1.67187.8K
Sep 15, 2026$2.00$2.00$1.50$1.52164.33K
Sep 14, 2026$2.01$2.075$1.97$2.0158.51K
Sep 11, 2026$2.06$2.0875$1.98$1.9837.6K
Sep 10, 2026$2.11$2.28$2.05$2.0621.99K
Sep 9, 2026$2.15$2.4699$2.05$2.0874.07K
Sep 8, 2026$2.08$2.2965$2.06$2.1227.67K

Latest RADX news

The latest Smart Investors Daily articles mentioning RADX.

Stock researchCompany · Overview

RADX research

Overview

Company profile and research snapshot.

Company profile

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
RADX recent ratings
DateFirmRatingTarget
Mar 26, 2026JONES TRADINGBuy—
Mar 25, 2026JONES TRADINGBuy—
Jan 31, 2026JONES TRADINGBuy—
Dec 17, 2025JONES TRADINGBuy—
Dec 16, 2025JONES TRADINGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Edison Issues Report on Starpharma (SPL)

London, United Kingdom--(Newsfile Corp. - September 30, 2026) - Edison issues report on Starpharma (ASX: SPL)Starpharma is a biotechnology company specialised in targeted oncology, underpinned by its proprietary, clinically established dendrimer enhanced product (DEP) platform. The investment case combines two approaches to value creation: retaining more favourable economics through internally developed targeted oncology assets, while partnered programmes broaden DEP's reach, validate the...

Yahoo · Sep 14, 2026

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol Brain Metastases Imaging has ~$600 million total addressable market, and there are no currently approved PET products SYDNEY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on

Yahoo · Sep 9, 2026

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceutical

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By